Skip to main content

Advertisement

Table 3 Multivariate analyses of overall survival in additional independent cases of BRCA, LIHC, LUAD, STAD, and ESCA

From: Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis

Cancer type Characteristic Total (cases) PGK1 pS203 PDHK1 pT338
HR (95% CI) P HR (95% CI) P
BRCA TNBCa
 No 109 1.000   1.000  
 Yes 24 2.561 (1.205–5.444) 0.014 2.532 (1.191 to 5.383) 0.016
TNM stageb
 I/II 95 1.000   1.000  
 III/IV 48 2.241 (1.172–4.286) 0.015 2.238 (1.174 to 4.265) 0.014
PGK1 pS203
 Low 65 1.000    
 High 80 1.596 (0.805–3.168) 0.181   
PDHK1 pT338
 Low 66    1.000  
 High 79    1.661 (0.837 to 3.298) 0.147
LIHC TNM stagec
 I/II 73 1.000   1.000  
 III/IV 104 2.853 (1.878 to 4.335) 0.000 2.905 (1.910 to 4.419) 0.000
PGK1 pS203
 Low 107 1.000    
 High 78 1.574 (1.064 to 2.327) 0.023   
PDHK1 pT338
 Low 105    1.000  
 High 80    2.060 (1.390 to 3.052) 0.000
LUAD TNM stage
 I/II 105 1.000   1.000  
 III/IV 74 1.805 (1.267 to 2.570) 0.001 1.828 (1.284 to 2.602) 0.001
PGK1 pS203
 Low 74 1.000    
 High 105 1.800 (1.238 to 2.617) 0.002   
PDHK1 pT338
 Low 75    1.000  
 High 104    1.634 (1.129 to 2.364) 0.009
STAD Age (years)
 ≤ 60 56 1.000   1.000  
 > 60 39 2.258 (1.441 to 3.538) 0.000 2.255 (1.436 to 3.540) 0.000
TNM staged
 I/II 24 1.000   1.000  
 III/IV 69 3.382 (1.957 to 5.843) 0.000 3.314 (1.920 to 5.720) 0.000
PGK1 pS203
 Low 51 1.000    
 High 44 2.603 (1.630 to 4.155) 0.000   
PDHK1 pT338
 Low 49    1.000  
 High 46    2.397 (1.501 to 3.829) 0.000
ESCA Age (years)
 ≤ 60 112 1.000   1.000  
 > 60 102 1.657 (1.146 to 2.397) 0.007 1.614 (1.114 to 2.338) 0.011
TNM stage
 I/II 98 1.000   1.000  
 III/IV 116 6.041 (3.867 to 9.437) 0.000 6.022 (3.852 to 9.415) 0.000
PGK1 pS203
 Low 103 1.000    
 High 111 1.440 (0.997 to 2.079) 0.052   
PDHK1 pT338
 Low 94    1.000  
 High 120    1.453 (0.996 to 2.119) 0.053
  1. BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, HR hazard ratio, 95% CI 95% confidence interval, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, PGK1 pS203 PGK1 S203 phosphorylation level, PDHK1 pT338 PDHK1 T338 phosphorylation level
  2. aThe data of TNBC in BRCA were available in 133 patients
  3. bThe data of TNM stage in BRCA were available in 143 patients
  4. cThe data of TNM stage in LIHC were available in 177 patients
  5. dThe data of TNM stage in STAD were available in 93 patients